Hypoglycemia induced by long-acting somatostatin analogues in a patient with nonfunctional neuroendocrine tumor
Articles > Article · 2009
Authors: I. T. Unek, Aygül ÇELTİK, S. Yener, T. Yavuzsen, A. Alacacioglu, S. Cokmert, I. Oztop, B. Demirkan, O. Dicle, O. Sagol, R. Bekis, U. Yilmaz
JOURNAL OF BUON, Journal Indexed in SCI Expanded, International, 2009, vol 14, pp 135-138
Summary
Somatostatin and its long-acting analogues are effective in symptom control in patients with functional neuroendocrine tumors; they are also able to control tumor growth. Somatostatin analogues are safe and generally well tolerated. In some cases they may cause serious complications.